Shopping Cart
Remove All
Your shopping cart is currently empty
SLC3037 is an NLRP3 inhibitor that prevents the binding or oligomerization of NLRP3 with NEK7, thereby inhibiting inflammasome activation triggered by MSU and other activators. It is suitable for research related to gout, cardiovascular diseases, metabolic syndrome, or neurodegenerative diseases.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Backorder | Backorder | |
| 50 mg | Inquiry | Backorder | Backorder |
| Description | SLC3037 is an NLRP3 inhibitor that prevents the binding or oligomerization of NLRP3 with NEK7, thereby inhibiting inflammasome activation triggered by MSU and other activators. It is suitable for research related to gout, cardiovascular diseases, metabolic syndrome, or neurodegenerative diseases. |
| In vitro | SLC3037 (1-10 μM, 5 h) exhibits a dose-dependent inhibitory effect on IL-1β in bone marrow-derived macrophages (BMDMs) induced by lipopolysaccharide and MSU. |
| Formula | C29H35N7OS |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.